Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Neoplasms Clinical Trial

Official title:

A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 14 Days in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02171637
• Other study ID #: 1200.1
• Status: Completed
• Phase: Phase 1
• First received: June 20, 2014
• Last updated: June 20, 2014
• Start date: November 2003

Study information

• Verified date: June 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Medicines Evaluation Board (MEB)
• Study type: Interventional

Clinical Trial Summary

Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective tumour responses

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. primary completion date: February 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumors, of types historically known to express EGFR and/or HER2, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment

• Age 18 years or older

• Life expectancy of at least three (3) months

• Written informed consent given that is consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines

• Eastern Cooperative Oncology Group (ECOG) performance score 0, 1, or 2

• Patients must have resolution of prior chemo-, hormone, immuno-, or radiotherapy-related toxicities to CTC Grade < 1

• Patients have to be recovered from previous surgery

• Paraffin-embedded tumor material must be accessible for analysis of EGFR and HER2-status.

• The additional 12 patients that were to be recruited at the MTD also had to fulfill the following criterion: Measurable tumor deposits (RECIST: Response Evaluation Criteria in Solid Tumors) by one or more techniques (X-ray, CT, MRI)

Exclusion Criteria:

• Active infectious disease

• Gastrointestinal disorders that might interfere with the absorption of the study drug or chronic diarrhea

• Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol

• Brain metastases requiring therapy as based on clinical symptoms

• Impaired cardiac left ventricular function with resting ejection fraction CTC Grade = 1

• Absolute neutrophil count (ANC) less than 1500 / mm3

• Platelet count less than 100 000 / mm3

• Bilirubin greater than 1.5 mg / dl (> 26 µmol / L, SI unit equivalent)

• Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)

• Serum creatinine greater than 1.5 mg / dl (> 132 µmol / L, SI (Systeme International) unit equivalent)

• Women and men who are sexually active and unwilling to use a medically acceptable method of contraception

• Pregnancy or breast-feeding

• Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (excluding LHRH agonists, other hormones taken for breast cancer, or bisphosphonates) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study

• Patients unable to comply with the protocol

• Active alcohol or drug abuse

RETREATMENT CRITERIA

The patient may be eligible for re-treatment after the previous course finished. The patient will not be eligible if the following criteria are met.

• Patients with clinical signs of disease progression or if an X-ray, CT or MRI was done and the test showed progressive disease

• Cardiac left ventricular function CTC Grade = 2 at any time during the previous course

• Patients fulfilling any of the Exclusion Criteria as mentioned under exclusion criteria on Day 29 of the previous course

• Patients not recovered from any dose-limiting toxicity (DLT) 14 days after the last administration of BIBW 2992 in the previous course. Recovery is defined as a return to baseline level or CTC Grade 1, whichever is higher

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BIBW 2992
escalating doses

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)		up to 28 months	No
Primary	Incidence and intensity of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) associated with increasing doses of BIBW 2992		up to 28 months	No
Secondary	Area under the plasma concentration-time curve (AUC) for different time points		up to 384 hours after first drug administration	No
Secondary	Predose plasma concentration (Cpre) for different time points		Day 8 and 14	No
Secondary	Minimum measured plasma concentration (Cmin) for different time points		up to 384 hours after first drug administration	No
Secondary	Maximum measured plasma concentration (Cmax) for different time points		up to 384 hours after first drug administration	No
Secondary	Time from dosing to the minimum plasma concentration (tmin) for different time points		up to 384 hours after first drug administration	No
Secondary	Time from dosing to the maximum plasma concentration (tmax) for different time points		up to 384 hours after first drug administration	No
Secondary	Terminal half-life (t1/2) for different time points		up to 384 hours after first drug administration	No
Secondary	Mean residence time after oral administration (MRTpo) for different time points		up to 384 hours after first drug administration	No
Secondary	Apparent clearance (CL/F) for different time points		up to 384 hours after first drug administration	No
Secondary	Apparent volume of distribution during the terminal phase (Vz/F) for different time points		up to 384 hours after first drug administration	No
Secondary	Accumulation ratio (RA)		up to 384 hours after first drug administration	No
Secondary	Modulation of biomarker (EGFR, p-EGFR, p-MAPK (mitogen-activated protein kinase), p-Akt, Ki-67, p-27KIP1) in skin biopsies prior to administration of BIBW 2992 and at the end of the first treatment period		Baseline and day 14	No
Secondary	Modulation of biomarker (EGFR, p-EGFR, HER2, p-MAPK, p-Akt, Ki-67, p-27KIP1) in tumor biopsies prior to administration of BIBW 2992 and at the end of the first treatment period in 6 or more patients treated at the MTD		Baseline and day 14	No
Secondary	Objective tumor responses		every 8 weeks up to 28 months	No
Secondary	Correlation of EGFR, HER2, estrogen receptor and progesterone receptor immunohistochemical status as based on tumor biopsies or excisions obtained prior to this trial with objective tumor responses		up to 28 months	No

External Links

•   Link